Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing

96-week resistance analyses of rilpivirine in treatment-naive, HIV-1-infected adults from the ECHO and THRIVE Phase III trials

(2013) Laurence Rimsky et al.   ANTIVIRAL THERAPY

Efficacy and Safety of Lersivirine (UK-453,061) Versus Efavirenz in Antiretroviral Treatment–Naive HIV-1–Infected Patients

(2013) Pietro Vernazza et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Significantly Improved HIV Inhibitor Efficacy Prediction Employing Proteochemometric Models Generated From Antivirogram Data

(2013) Gerard J. P. van Westen et al.   PLoS Computational Biology

Panel of Prototypical Recombinant Infectious Molecular Clones Resistant to Nevirapine, Efavirenz, Etravirine, and Rilpivirine

(2012) Maya Balamane et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antiviral Activity andIn VitroMutation Development Pathways of MK-6186, a Novel Nonnucleoside Reverse Transcriptase Inhibitor

(2012) Meiqing Lu et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Cross-validated stepwise regression for identification of novel non-nucleoside reverse transcriptase inhibitor resistance associated mutations

(2011) Koen Van der Borght et al.   BMC BIOINFORMATICS

Docking Analysis and Resistance Evaluation of Clinically Relevant Mutations Associated with the HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors Nevirapine, Efavirenz and Etravirine

(2011) Stefano Alcaro et al.   ChemMedChem

Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine

(2011) Lotke Tambuyzer et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

The HIV-1 Reverse Transcriptase M184I Mutation Enhances the E138K-Associated Resistance to Rilpivirine and Decreases Viral Fitness

(2011) Rima Kulkarni et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies

(2011) Laurence Rimsky et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy

(2011) Roger Paredes et al.   JOURNAL OF INFECTIOUS DISEASES

Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies

(2010) Johan Vingerhoets et al.   AIDS

TMC278, a Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI), Active against Wild-Type and NNRTI-Resistant HIV-1

(2009) H. Azijn et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Nonpolymorphic Human Immunodeficiency Virus Type 1 Protease and Reverse Transcriptase Treatment-Selected Mutations

(2009) R. Shahriar et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY